Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells.

Carpin LB, Bickford LR, Agollah G, Yu TK, Schiff R, Li Y, Drezek RA.

Breast Cancer Res Treat. 2011 Jan;125(1):27-34. doi: 10.1007/s10549-010-0811-5. Epub 2010 Mar 10.

PMID:
20217215
2.

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ.

Nat Clin Pract Oncol. 2006 May;3(5):269-80. Review.

PMID:
16683005
3.

Her2-positive breast cancer: herceptin and beyond.

Dean-Colomb W, Esteva FJ.

Eur J Cancer. 2008 Dec;44(18):2806-12. doi: 10.1016/j.ejca.2008.09.013. Epub 2008 Nov 18. Review.

PMID:
19022660
4.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Review.

PMID:
21115425
5.

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.

Morris SR, Carey LA.

Oncology (Williston Park). 2006 Dec;20(14):1763-71; discussion 1771-2, 1774-6. Review.

6.

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.

PMID:
19884552
7.

Evolving novel anti-HER2 strategies.

Jones KL, Buzdar AU.

Lancet Oncol. 2009 Dec;10(12):1179-87. doi: 10.1016/S1470-2045(09)70315-8. Review.

PMID:
19959074
8.

Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.

Huang Y, Fu P, Fan W.

Curr Drug Targets. 2013 Jul;14(8):889-98. Review.

PMID:
23531110
9.

Mechanisms of trastuzumab resistance in breast cancer.

Tolaney SM, Krop IE.

Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. Review.

PMID:
19275526
10.

HER2 therapy: molecular mechanisms of trastuzumab resistance.

Nahta R, Esteva FJ.

Breast Cancer Res. 2006;8(6):215. Review.

11.

Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.

Subbiah IM, Gonzalez-Angulo AM.

Curr Treat Options Oncol. 2014 Mar;15(1):41-54. doi: 10.1007/s11864-013-0262-4. Review.

12.

Macrophages as cell-based delivery systems for nanoshells in photothermal therapy.

Madsen SJ, Baek SK, Makkouk AR, Krasieva T, Hirschberg H.

Ann Biomed Eng. 2012 Feb;40(2):507-15. doi: 10.1007/s10439-011-0415-1. Epub 2011 Oct 7. Review.

13.

Theranostic nanoshells: from probe design to imaging and treatment of cancer.

Bardhan R, Lal S, Joshi A, Halas NJ.

Acc Chem Res. 2011 Oct 18;44(10):936-46. doi: 10.1021/ar200023x. Epub 2011 May 25. Review.

14.

Light-activatable gold nanoshells for drug delivery applications.

Singhana B, Slattery P, Chen A, Wallace M, Melancon MP.

AAPS PharmSciTech. 2014 Jun;15(3):741-52. doi: 10.1208/s12249-014-0097-8. Epub 2014 Feb 19. Review.

15.

Advances in cancer research using gold nanoparticles mediated photothermal ablation.

Mocan L, Matea CT, Bartos D, Mosteanu O, Pop T, Mocan T, Iancu C.

Clujul Med. 2016;89(2):199-202. doi: 10.15386/cjmed-573. Epub 2016 Apr 15. Review.

16.

Laser thermal ablation of multidrug-resistant bacteria using functionalized gold nanoparticles.

Mocan L, Tabaran FA, Mocan T, Pop T, Mosteanu O, Agoston-Coldea L, Matea CT, Gonciar D, Zdrehus C, Iancu C.

Int J Nanomedicine. 2017 Mar 23;12:2255-2263. doi: 10.2147/IJN.S124778. eCollection 2017. Review.

Supplemental Content

Support Center